Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 5

Augmentation treatment in major depressive disorder: focus on aripiprazole

Authors J Craig Nelson, Andrei Pikalov, Robert M Berman

Published 10 October 2008 Volume 2008:4(5) Pages 937—948


Review by Single-blind

Peer reviewer comments 3

J Craig Nelson1, Andrei Pikalov2, Robert M Berman3

1University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USA

Abstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.

Keywords: major depression, antipsychotic, mood disorder, aripiprazole

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R

Neuropsychiatric Disease and Treatment 2011, 7:303-312

Published Date: 24 May 2011

Readers of this article also read:

Bladder cancer in the elderly patient: challenges and solutions

Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, Mohile SG, Fung C

Clinical Interventions in Aging 2015, 10:939-949

Published Date: 10 June 2015

Predictors of quality of life among individuals with schizophrenia

Suttajit S, Pilakanta S

Neuropsychiatric Disease and Treatment 2015, 11:1371-1379

Published Date: 28 May 2015

Dietary patterns and schizophrenia: a comparison with healthy controls

Tsuruga K, Sugawara N, Sato Y, Saito M, Furukori H, Nakagami T, Nakamura K, Takahashi I, Nakaji S, Yasui-Furukori N

Neuropsychiatric Disease and Treatment 2015, 11:1115-1120

Published Date: 22 April 2015

Cyclophosphamide-induced symptomatic hyponatremia, a rare but severe side effect: a case report

Elazzazy S, Mohamed AE, Gulied A

OncoTargets and Therapy 2014, 7:1641-1645

Published Date: 30 September 2014

Perioperative and postoperative risk factors for corneal graft failure

Yu AL, Kaiser M, Schaumberger M, Messmer E, Kook D, Welge-Lussen U

Clinical Ophthalmology 2014, 8:1641-1647

Published Date: 28 August 2014

Potential of antibody–drug conjugates and novel therapeutics in breast cancer management

Lianos GD, Vlachos K, Zoras O, Katsios C, Cho WC, Roukos DH

OncoTargets and Therapy 2014, 7:491-500

Published Date: 24 March 2014

Treating malignant glioma in Chinese patients: update on temozolomide

Chang L, Su J, Jia X, Ren H

OncoTargets and Therapy 2014, 7:235-244

Published Date: 12 February 2014

Visual and refractive outcome of one-site phacotrabeculectomy compared with temporal approach phacoemulsification

Daniela Vaideanu, Kaveri Mandal, Anthony Hildreth, Scott G Fraser, Peter S Phelan

Clinical Ophthalmology 2008, 2:569-574

Published Date: 12 September 2008